The three largest U.S. drug distributors and drugmaker Johnson & Johnson agreed to finalize a proposed $26 billion settlement resolving claims by states and local governments that they helped fuel the U.S. opioid epidemic.
Drugmaker Shionogi applied for approval to make and sell the company’s oral COVID-19 treatment in Japan, the firm said on February 25.
The Omicron BA.2 sub-variant of COVID-19 appears to be more infectious than the original BA.1 sub-variant, but does not cause more severe disease, the head of Africa’s top public health body said on February 24 citing data from South Africa.
Medicago’s vaccine on February 24 became the world’s first plant-based shot approved against COVID-19 after Health Canada cleared Covifenz for use in adults.
Extending the interval between the first two doses of the most widely used COVID-19 vaccines in the country to eight weeks for young men can reduce the rare risk of heart inflammation, U.S. health officials said.
The global project to share COVID-19 vaccines is struggling to place more than 300 million doses in the latest sign the problem with vaccinating the world is now more about demand than supply.
A large study into rare blood clots linked with AstraZeneca’s COVID-19 vaccine found between just one and three cases per million, and only after the first dose, shedding fresh light on the side effects from the shot.
The Centers for Disease Control and Prevention (CDC) awarded Palantir Technologies Inc. a $5.3 million contract to manage distribution of COVID-19 drugs in the United States, the software maker said on February 22.
Lilly is investing $700 million to build a state-of-the-art facility in the Boston Seaport, as part of plans to advance the company’s RNA-based research and development activities.
Getting infected twice with two different Omicron coronavirus subvariants is possible, but rarely happens, a Danish study has found.
